Reduction of galectin-3 expression reduces pituitary tumor cell progression

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 6892-6898

  Huang, C X ^a   Zhao, J N ^a   Zou, W H ^a   Li, J J ^a   Wang, P C ^a   Liu, C H ^a   Wang, Y B ^a  

^a HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Cell apoptosis; Galectin 3; Pituitary neoplasm

Indexed keywords

GALECTIN 3; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HYPOPHYSIS TUMOR; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH; ANIMAL; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE;

EID: 84907149980     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.August.29.11     Document Type: Article

References (19)

1. Arfaoui-Toumi A, Kria-Ben ML, Ben HM, Khalfallah MT, et al. (2010). Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bull. Cancer 97: E1-E8.
2. Bresalier RS, Yan PS, Byrd JC, Lotan R, et al. (1997). Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80: 776-787.
3. Deininger MH, Trautmann K, Meyermann R and Schluesener HJ (2002). Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. Anticancer Res. 22: 1585-1592.
4. Fukumori T, Kanayama HO and Raz A (2007). The role of galectin-3 in cancer drug resistance. Drug Resist. Updat. 10: 101-108.
5. Goetz JG (2009). Bidirectional control of the inner dynamics of focal adhesions promotes cell migration. Cell Adh. Migr. 3: 185-190.
6. Gordower L, Decaestecker C, Kacem Y, Lemmers A, et al. (1999). Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol. 25: 319-330.
7. Huang CX, Hou YH and Liu YS (2008). Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. Neurosci. Bull. 24: 34-38.
8. Jia W, Kidoya H, Yamakawa D, Naito H, et al. (2013). Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am. J. Pathol. 182: 1821-1831.
9. Lee J, Moon C, Kim J, Jung C, et al. (2009). Immunohistochemical localization of galectin-3 in the granulomatous lesions of paratuberculosis-infected bovine intestine. J. Vet. Sci. 10: 177-180.
10. Liu FT and Rabinovich GA (2005). Galectins as modulators of tumour progression. Nat. Rev. Cancer 5: 29-41.
11. Manivannan P, Siddaraju N, Jatiya L and Verma SK (2012). Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian J. Biochem. Biophys. 49: 392-394.
12. Nakahara S, Oka N and Raz A (2005). On the role of galectin-3 in cancer apoptosis. Apoptosis 10: 267-275.
13. Nangia-Makker P, Balan V and Raz A (2008). Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron. 1: 43-51.
14. Sakaki M, Fukumori T, Fukawa T, Elsamman E, et al. (2010). Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J. Med. Invest. 57: 152-157.
15. Strik HM, Deininger MH, Frank B, Schluesener HJ, et al. (2001). Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J. Neurooncol. 53: 13-20.
16. Vladimirova V, Waha A, Luckerath K, Pesheva P, et al. (2008). Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J. Neurosci. Res. 86: 2450-2461.
17. Wu SW, Yu L, Zhou L, Cheng ZN, et al. (2013). Expression of Gal-3 and CD82/KAI1 proteins in non-small cell lung cancer and their clinical significance. Zhonghua Zhong Liu Za Zhi 35: 124-128.
18. Yamaki S, Fujii T, Yajima R, Hirakata T, et al. (2013). Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg. Today 43: 901-905.
19. Zhang HY, Jin L, Stilling GA, Ruebel KH, et al. (2009). RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 35: 101-111.